(R)-CR8 (CR8) trihydrochloride 是 Roscovitine 的第二代类似物,是一种有效的CDK1/2/5/7/9抑制剂。(R)-CR8 trihydrochloride 抑制 CDK1/cyclin B (IC50=0.09 μM)、CDK2/cyclin A (0.072 μM)、CDK2/cyclin E (0.041 μM)、CDK5/p25 (0.11 μM)、CDK7/cyclin H (1.1 μM)、CDK9/cyclin T (0.18 μM) 和 CK1δ/ε (0.4 μM)。(R)-CR8 trihydrochloride 诱导细胞凋亡并具有神经保护作用。(R)-CR8 trihydrochloride 作为一种分子胶降解剂来消耗细胞周期蛋白 K。
生物活性 | (R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potentCDK1/2/5/7/9inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride inducesapoptosisand has neuroprotective effect[1][2]. (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K[3]. |
IC50& Target[1] | CDK1/cyclinB1 0.09 μM (IC50) | cdk2/cyclin A 0.072 μM (IC50) | CDK2/cyclinE 0.041 μM (IC50) | Cdk5/p25 0.11 μM (IC50) | CDK7/cyclin H 1.1 μM (IC50) | CDK9/Cyclin T 0.18 μM (IC50) | CK1δ/ε 0.4 μM (IC50) |
|
体外研究 (In Vitro) | (R)-CR8 (CR8) trihydrochloride (0.1-100 μM; 48 hours) is a potent inducer of apoptotic cell death with an IC50of 0.49 μM for SH-SY5Y cell line[1]. (R)-CR8 trihydrochloride (0.25-10 μM) induces a dose-dependent induction of poly-(ADP-ribose)polymerase (PARP) cleavage[1]. The CDK-bound form of (R)-CR8 trihydrochloride has a solvent-exposed pyridyl moiety that induces the formation of a complex between CDK12-cyclin K and the CUL4 adaptor protein DDB1, bypassing the requirement for a substrate receptor and presenting cyclin K for ubiquitination and degradation
Apoptosis Analysis[1] Cell Line: | SH-SY5Y cell line | Concentration: | 0.1, 1, 10, 100 μM | Incubation Time: | 24 hours | Result: | Reduced cell survival in a dose-dependent manner. |
|
体内研究 (In Vivo) | (R)-CR8 trihydrochloride (5 mg/Kg; i.p.) results in a significant reduction in lesion size at 28 days in histological assessment[2].
Animal Model: | Adult (10 to 12 weeks old) male Sprague-Dawley rats (310 to 330 g)[2] | Dosage: | 5 mg/Kg | Administration: | i.p. | Result: | Resulted in a significant reduction in lesion size. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 50 mg/mL(92.44 mM;Need ultrasonic) 配制储备液 1 mM | 1.8487 mL | 9.2435 mL | 18.4870 mL | 5 mM | 0.3697 mL | 1.8487 mL | 3.6974 mL | 10 mM | 0.1849 mL | 0.9244 mL | 1.8487 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.17 mg/mL (4.01 mM); Clear solution
此方案可获得 ≥ 2.17 mg/mL (4.01 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.17 mg/mL (4.01 mM); Clear solution
此方案可获得 ≥ 2.17 mg/mL (4.01 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.17 mg/mL (4.01 mM); Clear solution
此方案可获得 ≥ 2.17 mg/mL (4.01 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|